Role of Coenzyme Q10 in Female Fertility

Not on evidence anyone should call settled. The largest pooled analysis specific to CoQ10 covers six randomised controlled trials with 1,529 participants, all of them women with diminished ovarian reserve taking CoQ10 as a pretreatment before IVF or ICSI. Its primary reported outcome is clinical pregnancy — OR 1.84, 95% CI 1.33 to 2.53 — and not live birth (Lin et al, Annals of Medicine 2024;56(1):2389469). The authors add that the trials they pooled had relatively limited sample sizes and poor descriptions of their methodology, and that rigorously conducted trials are still needed.

The one live birth signal retrieved comes from a network meta-analysis of 16 randomised trials in 2,323 women with poor ovarian response defined by the Bologna criteria, where CoQ10 ranked highest for live birth (OR 2.36, 95% CI 1.07 to 5.38) (Zhu et al, Reproductive Biology and Endocrinology 2023;21:64). A network meta-analysis compares treatments partly through indirect routes rather than head to head, and that confidence interval nearly touches 1. It is a reason to keep studying CoQ10, not a demonstrated live birth benefit.

Cochrane, assessing all oral antioxidants together including CoQ10 across 63 trials and 7,760 women, rates the live birth evidence as very low quality: OR 1.81, 95% CI 1.36 to 2.43 from 13 RCTs and 1,227 women, which against an expected live birth rate of 19% would put the rate with antioxidants between 24% and 36%. Its conclusion is that there is limited evidence in support of supplemental oral antioxidants for subfertile women (Showell et al, Cochrane Database of Systematic Reviews 2020, CD007807).

This is the question that decides whether any of the above applies to a given person, and the answer is narrower than the marketing. Across every trial retrieved for this article, the participants fell into two groups:

• Women with diminished ovarian reserve or poor ovarian response going through IVF or ICSI — defined by the Bologna criteria in the network meta-analyses, and by POSEIDON group 3 (under 35, with poor ovarian reserve parameters) in the largest single randomised trial.
• Women with polycystic ovary syndrome who had not ovulated on clomiphene citrate, taking CoQ10 alongside a further clomiphene course.

No retrieved trial tested CoQ10 in people with normal ovarian reserve trying to conceive without treatment. That is the largest group buying it, and the group for whom there is no trial evidence at all. If the starting question is what the reserve tests actually mean, what a diminished ovarian reserve result does and does not tell you covers that first.

The evidence is stronger for quantity and process than for quality. In the Lin pooled analysis the number of oocytes retrieved rose by 1.30 (95% CI 1.21 to 1.40), the cycle cancellation rate fell (OR 0.60, 95% CI 0.44 to 0.83) across the same 1,529 participants, and the total gonadotrophin dose fell by 330 units. A separate network meta-analysis of adjuvants in poor responders found CoQ10 produced the lowest cycle cancellation rate of the ten treatments compared (OR 0.33, 95% CI 0.15 to 0.74) (Zhang et al, Human Reproduction Update 2020;26(2):247-63).

The single randomised trial that looked hardest at embryology is Xu and colleagues' study of 169 evaluated patients under 35 with poor ovarian reserve, randomised to 60 days of CoQ10 pretreatment or none. The CoQ10 group needed less gonadotrophin, retrieved more oocytes, produced more high-quality embryos, and had fewer transfers cancelled for poor embryo development (8.33% versus 22.89%, p=0.04); more of them had embryos available to freeze (18.42% versus 4.3%, p=0.012). Clinical pregnancy and live birth rates, per transfer and per complete stimulation cycle, tended to be higher but did not reach statistical significance (Reproductive Biology and Endocrinology 2018;16(1):29).

On chromosomal quality directly, the answer is that nobody finished the experiment. A double-blind placebo-controlled trial in IVF-ICSI patients aged 35 to 43 measured post-meiotic oocyte aneuploidy by polar body biopsy and was terminated early over safety concerns about the biopsy itself. Aneuploidy was 46.5% with CoQ10 versus 62.8% with placebo and clinical pregnancy 33% versus 26.7%, but no significant difference was detected and the authors state the study was underpowered (Bentov et al, Clinical Medicine Insights: Reproductive Health 2014;8:31-6).

The tested doses disagree with each other by a factor of twenty, which is the most useful thing to know about them:

• 600 mg a day. Used in the Bentov trial, and in the Xu trial as 200 mg three times daily for 60 days before the cycle. The Xu authors write that the optimal timing, duration and dose remain unclear, and that their own choice of dose was a rather intuitive one guided by earlier studies.
• 120 mg a day, alongside clomiphene, in the PCOS trial described below. Those authors record that there is no definite evidence on optimal dosing and that the commonly recommended dose is between 100 and 200 mg.
• 30 mg a day for 3 months before the stimulation cycle. This is what a meta-analysis of 20 randomised trials in 2,617 participants with ovarian aging identified as the regimen associated with improved pregnancy rate, with better effects more pronounced at lower doses (Shang et al, Advances in Nutrition 2024;15(8):100273).

No source retrieved for this article recommends a dose for fertility, and this page does not either. On tolerability, the Xu authors cite evidence that CoQ10 is well tolerated and safe in healthy adults at intakes up to 900 mg a day, and Cochrane found no evidence of a difference between antioxidant and control groups in gastrointestinal disturbance (OR 1.55, 95% CI 0.47 to 5.10; 3 RCTs, 343 women), miscarriage (OR 1.13; 24 RCTs, 3,229 women) or multiple pregnancy (OR 1.00; 9 RCTs, 1,886 women), all on low quality evidence.

There is one retrievable, non-retracted randomised trial. In 149 women with clomiphene-resistant PCOS randomised in Karachi, with 133 assessed, adding CoQ10 to clomiphene citrate was associated with ovulation in 70% versus 19% of women (p=0.001) and conception per cycle in 48.6% versus 6.3% (p<0.001); stratified by weight, 85.3% of non-obese women in the combination group ovulated versus 55.6% of obese women (p=0.002) (Izhar et al, Journal of Reproduction and Infertility 2022;23(3):177-83).

The correction matters more than the result. The trial this finding is usually attributed to — El Refaeey, Selem and Badawy, Reproductive BioMedicine Online 2014;29(1):119-24, reporting ovulation in 65.9% of 82 cycles versus 15.5% of 71 control cycles — carried an expression of concern in 2022 and was formally retracted in 2023 (Reproductive BioMedicine Online 2023;47(5):103389). It is still cited across supplement pages and in the discussion sections of later papers. It should not be treated as evidence, and no claim on this page rests on it.

Clomiphene resistance is a specific clinical situation, not a general PCOS description. How PCOS affects conception sets out where ovulation induction sits in the sequence, and what is usually tried before it.

No guideline retrieved for this article recommends it, and the most relevant one does not mention it. ESHRE's 2019 guideline on ovarian stimulation for IVF/ICSI contains no reference to coenzyme Q10 or to antioxidants anywhere in its text. The adjuvants it does assess it advises against: routine metformin is not recommended with the antagonist protocol in PCOS, and growth hormone, testosterone, dehydroepiandrosterone, aspirin and sildenafil are each not recommended for poor responders.

That silence is not a verdict against CoQ10. It means the guideline group did not put a recommendation either way, so anyone citing ESHRE in support of CoQ10 is citing something that is not there. The nearest thing to a guideline-level statement is Cochrane's: limited evidence in support of supplemental oral antioxidants for subfertile women.

One footnote on that Cochrane review, because it bears on how much weight the whole field can carry. An editorial note added in March 2026 records that nine of its included studies have since attracted retractions (seven) or expressions of concern (two). Cochrane's editors assessed the impact and retained confidence in the review's conclusions, and will exclude those studies at the next update.

Several claims commonly attached to CoQ10 are not supported by the sources here.

• That CoQ10 improves egg quality. What has been measured is oocyte yield, embryo grading and cancellation rates. The one trial that measured chromosomal status directly was terminated early and found no significant difference.
• That it raises live birth rates. The specific CoQ10 meta-analysis reports clinical pregnancy; the single live birth estimate comes from an indirect network comparison with a confidence interval running from 1.07 to 5.38; and Cochrane rates the antioxidant live birth evidence very low quality.
• That it helps anyone trying to conceive. Every trial retrieved enrolled either diminished ovarian reserve or clomiphene-resistant PCOS. There is no trial evidence for general use.
• That there is a correct dose. Tested doses run from 30 mg to 600 mg a day, the largest meta-analysis by participant count favours the low end, and the trial authors themselves describe the choice as unresolved.
• That it works through improving mitochondrial function in eggs. That is the stated rationale in these papers, not a finding any of them measured in humans.
• That dietary CoQ10 is relevant. No source retrieved here measured food intake of CoQ10 against any fertility outcome, so the live article's dietary-sources section has been removed rather than rewritten.
• That the 2014 PCOS trial supports any of this. It was retracted in 2023.

What is established is narrow: in women with diminished ovarian reserve going into IVF, CoQ10 pretreatment is associated with more oocytes, fewer cancelled cycles, less gonadotrophin and a higher clinical pregnancy rate, on trials the reviewers themselves call small and poorly reported. Where supplements sit relative to everything else that affects an outcome is covered in what actually changes egg quality, and what cannot and which fertility supplements have evidence behind them.